Literature DB >> 28361297

Neuropathic pain in patients with sickle cell disease: a cross-sectional study assessing teens and young adults.

Fabricio Dias Antunes1, Vynicius Goltran Sobral Propheta2, Hulemar Andrade Vasconcelos2, Rosana Cipolotti2.   

Abstract

Chronic pain conditions are little studied and may be underestimated in sickle cell disease (SCD). The aim of this study was to identify the occurrence and characteristics of neuropathic pain (NP) in SCD patients. A sample of 56 patients was chosen from a total of 554 patients submitted to the inclusion criteria between 2015 and 2016. The Leeds assessment of neuropathic symptoms and signs scale was used for detecting NP. The groups with and without NP were compared by sex, age, use of hydroxyurea, and sensory changes through Chi-square, Fisher's exact, ANOVA, and Kruskal-Wallis tests. The average age was 20.6 years (SD ± 4.6), 51.8% of the patients were male, and 14 patients (25%) suffered from NP. Most commonly, the pain was reported to be in the lower back area (53.6%). Age was positively related to NP: the average age in the group with NP was 22.7 years (SD ± 4.1) and in the group without NP was 19.8 years (SD ± 4.5), p < 0.05. Higher rates of NP occurred in patients aged 19 years or older, compared with that in teens (p < 0.01). There was a positive association between NP and the use of hydroxyurea (p < 0.05). An association was found between NP and sensitive neurological changes (p < 0.01). Therefore, screening for NP may result in faster and more effective diagnoses and consequently initiate appropriate treatment.

Entities:  

Keywords:  Chronic pain; Hydroxyurea; Neuropathic pain; Sickle cell

Mesh:

Substances:

Year:  2017        PMID: 28361297     DOI: 10.1007/s00277-017-2984-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

1.  A QST-based Pain Phenotype in Adults With Sickle Cell Disease: Sensitivity and Specificity of Quality Descriptors.

Authors:  Brenda W Dyal; Miriam O Ezenwa; Saunjoo L Yoon; Roger B Fillingim; Yingwei Yao; Judith M Schlaeger; Marie L Suarez; Zaijie J Wang; Robert E Molokie; Diana J Wilkie
Journal:  Pain Pract       Date:  2019-10-18       Impact factor: 3.183

Review 2.  Pain-measurement tools in sickle cell disease: where are we now?

Authors:  Deepika S Darbari; Amanda M Brandow
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  Prevalence of neuropathic pain in adolescents with sickle cell disease: A single-center experience.

Authors:  Melissa Cregan; Latika Puri; Guolian Kang; Doralina Anghelescu
Journal:  Pediatr Blood Cancer       Date:  2022-02-11       Impact factor: 3.167

4.  Screening for neuropathic pain in patients with sickle cell disease: is a single assessment scale sufficient?

Authors:  Fabricio Dias Antunes; Cidson Leonardo Silva Junior; Karine Santos Cerqueira; Maira do Livramento Faro; Rosana Cipolotti
Journal:  Orphanet J Rare Dis       Date:  2019-05-14       Impact factor: 4.123

5.  Patients with sickle-cell disease exhibit greater functional connectivity and centrality in the locus coeruleus compared to anemic controls.

Authors:  Ravi R Bhatt; Lonnie K Zeltzer; Julie Coloigner; John C Wood; Tom D Coates; Jennifer S Labus
Journal:  Neuroimage Clin       Date:  2019-01-22       Impact factor: 4.881

Review 6.  Moving Toward a Multimodal Analgesic Regimen for Acute Sickle Cell Pain with Non-Opioid Analgesic Adjuncts: A Narrative Review.

Authors:  Martha O Kenney; Wally R Smith
Journal:  J Pain Res       Date:  2022-03-31       Impact factor: 3.133

Review 7.  Neuropathic pain in children: Steps towards improved recognition and management.

Authors:  Suellen M Walker
Journal:  EBioMedicine       Date:  2020-11-25       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.